Breadcrumb Home Studies Studies Search Filter Research Area AllComplications & ComorbiditiesCureTreatmentTuberculosis Study Status AllClosed to AccrualClosed to Follow UpConcludedEnrollingIn DevelopmentOpen to AccrualParticipants Off Study and Primary Analysis CompletedPending Sort Study Number AscStudy Number Desc Submit Search Showing 10 studies. IMPAACT 2018: Randomized Phase I Study of the Infectivity, Safety, and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV delta NS2/delta 1313/I1314L or RSV 276 or Placebo, Delivered as Nose Drops to RSV-Seronegative Infants 6 to 24 Months of Age DAIDS Number 38405 Research Area Complications & Comorbidities Study Status Concluded IMPAACT 2013: Phase I Placebo-Controlled Study of the Infectivity, Safety and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, D46/NS2/N/delta M2-2-HindIII, Lot RSV#011B, Delivered as Nose Drops to RSV-Seronegative Infants 6 to 24 Months of Age DAIDS Number 30074 Research Area Complications & Comorbidities Study Status Concluded IMPAACT 2012: Phase I Placebo-Controlled Study of the Infectivity, Safety and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, LID cp delta M2-2, Lot RSV#009B, Delivered as Nose Drops to RSV-Seronegative Infants 6 to 24 Months of Age DAIDS Number 30073 Research Area Complications & Comorbidities Study Status Concluded IMPAACT 2011: Phase I Placebo-Controlled Study of the Infectivity, Safety and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, LID delta M2-2 1030s, Lot RSV#010A, Delivered as Nose Drops to RSV-Seronegative Infants 6 to 24 Months of Age DAIDS Number 30072 Research Area Complications & Comorbidities Study Status Concluded IMPAACT 2000: A Phase I Study of the Safety and Immunogenicity of Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine RSV LID delta M2-2 in RSV-Seronegative Infants and Children DAIDS Number 12016 Research Area Complications & Comorbidities Study Status Concluded P1114: Safety and Immunogenicity of an RSV Vaccine cps2 DAIDS Number 11948 Research Area Complications & Comorbidities Study Status Concluded P1076: Impact of Oral Alendronate Therapy on BMD in HIV-Infected Children/Adolescents DAIDS Number 10669 Research Area Complications & Comorbidities Study Status Concluded P1074: IMPAACT LTFU Study DAIDS Number 10660 Research Area Complications & Comorbidities Study Status Concluded P1072: Safety and Immunogenicity of a Live, Attenuated, Rotavirus Vaccine (RotaTeqâ„¢) in HIV-1 Infected and Uninfected Children Born to HIV-1 Infected Mothers DAIDS Number 10638 Research Area Complications & Comorbidities Study Status Concluded P1063: Phase I/II Safety and Efficacy Investigation of Atorvastatin for Treatment of Increased LDL-Cholesterol in HIV-Infected children, Adolescents, and Young Adults DAIDS Number 10167 Research Area Complications & Comorbidities Study Status Concluded
IMPAACT 2018: Randomized Phase I Study of the Infectivity, Safety, and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV delta NS2/delta 1313/I1314L or RSV 276 or Placebo, Delivered as Nose Drops to RSV-Seronegative Infants 6 to 24 Months of Age DAIDS Number 38405 Research Area Complications & Comorbidities Study Status Concluded
IMPAACT 2013: Phase I Placebo-Controlled Study of the Infectivity, Safety and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, D46/NS2/N/delta M2-2-HindIII, Lot RSV#011B, Delivered as Nose Drops to RSV-Seronegative Infants 6 to 24 Months of Age DAIDS Number 30074 Research Area Complications & Comorbidities Study Status Concluded
IMPAACT 2012: Phase I Placebo-Controlled Study of the Infectivity, Safety and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, LID cp delta M2-2, Lot RSV#009B, Delivered as Nose Drops to RSV-Seronegative Infants 6 to 24 Months of Age DAIDS Number 30073 Research Area Complications & Comorbidities Study Status Concluded
IMPAACT 2011: Phase I Placebo-Controlled Study of the Infectivity, Safety and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, LID delta M2-2 1030s, Lot RSV#010A, Delivered as Nose Drops to RSV-Seronegative Infants 6 to 24 Months of Age DAIDS Number 30072 Research Area Complications & Comorbidities Study Status Concluded
IMPAACT 2000: A Phase I Study of the Safety and Immunogenicity of Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine RSV LID delta M2-2 in RSV-Seronegative Infants and Children DAIDS Number 12016 Research Area Complications & Comorbidities Study Status Concluded
P1114: Safety and Immunogenicity of an RSV Vaccine cps2 DAIDS Number 11948 Research Area Complications & Comorbidities Study Status Concluded
P1076: Impact of Oral Alendronate Therapy on BMD in HIV-Infected Children/Adolescents DAIDS Number 10669 Research Area Complications & Comorbidities Study Status Concluded
P1074: IMPAACT LTFU Study DAIDS Number 10660 Research Area Complications & Comorbidities Study Status Concluded
P1072: Safety and Immunogenicity of a Live, Attenuated, Rotavirus Vaccine (RotaTeqâ„¢) in HIV-1 Infected and Uninfected Children Born to HIV-1 Infected Mothers DAIDS Number 10638 Research Area Complications & Comorbidities Study Status Concluded
P1063: Phase I/II Safety and Efficacy Investigation of Atorvastatin for Treatment of Increased LDL-Cholesterol in HIV-Infected children, Adolescents, and Young Adults DAIDS Number 10167 Research Area Complications & Comorbidities Study Status Concluded